Infanrix-IPV is given as a booster vaccine at 4 years of age. The primary course of these vaccines (diphtheriatetanuspertussis[lso called whooping cough]polio) are included in the Infanrix-hexa vaccine given at 6 weeks, 3 months and 5 months.
Infanrix-IPV is funded as a booster vaccine at 4 years of age.
Infanrix-IPV is not funded for special groups.
Infanrix-IPV is funded for use in catch-up schedules for children up to their 10th birthday.
No special considerations, store as per cold chain between 2°C to 8°C.
Infanrix-IPV can be administered concurrently with other vaccines, including all the National Immunisation Schedule vaccines. Separate syringes and different injection sites should be used.
The vaccine is given intramuscularly in either the vastus lateralis or deltoid.
Infanrix-IPV should not be administered to children after their 10th birthday, or to adults. Refer to Appendix 2 in the current Immunisation Handbook for further details on catch-up schedules and doses
In the case of a child with a clinically unstable evolving neurological disorder, withholding vaccination until the clinical situation has stabilised should be considered on an individual basis after careful consideration of the risks and benefits.
Children with a personal history of a hypotonic hyporesponsive episode (HHE) can have the vaccine.
Infanrix-IPV can be given to a child with a family history of Sudden Unexplained Death of an Infant (SUDI) or convulsions following a diphtheria, tetanus and pertussis vaccination.
After administration of a booster dose of Infanrix-IPV more than 99.5% of children demonstrated protective antibody titre of >0.1 IU/mLs against tetanus and diphtheria. All vaccine recipients demonstrated a marked increase in protective antibody levels, with respect to pre-booster levels, against all three serotypes of polio covered by the vaccine.
After administration of a booster dose of Infanrix-IPV a booster response was also seen in the majority of vaccinees against the pertussis antigens; lower response rates were seen where the pre-vaccination levels of antibodies were high. All vaccine recipients were seropositive one month after the booster dose, however, it should be noted no serological correlation of protection has been established for pertussis. Collection of data from secondary contacts, in households where there was an index case with pertussis, found that the protective efficacy of the vaccine was 84-88.7%.